Neumora Q1 net loss $68M, secures $125M venture debt; navacaprant Ph3 data in 2026

Neumora Therapeutics, Inc.

2025-Q1 EPS reported -$0.42

Net loss $68.0M in Q1 2025, up from $53.7M in Q1 2024; R&D expense $52.2M (incl. $6.3M final Amgen costs).
Cash, equivalents and marketable securities $249.4M as of March 31; plus $20M drawn from K2 HealthVentures extends cash runway into 2027.
Entered $125M venture debt facility with K2 HealthVentures; $20M drawn, additional $20M available by Dec 31, 2025, $85M milestone-based.
Navacaprant KOASTAL-3 topline data expected Q1 2026, KOASTAL-2 Q2 2026; NMRA-511 AD agitation data around end of 2025.
M4 positive allosteric modulator (PAM) program expected to enter clinic in mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.